Testosterone hexahydrobenzoate
Clinical data | |
---|---|
Trade names | Testormon Depot, Sterandryl Retard, Tardosterandryl, Testodur, Virex |
Other names | THHB; Testosterone cyclohexanecarboxylate; TCHC; Testosterone 17β-cyclohexanecarboxylate |
Routes of administration | Intramuscular injection |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
ECHA InfoCard | 100.034.571 |
Chemical and physical data | |
Formula | C26H38O3 |
Molar mass | 398.587 g·mol−1 |
3D model (JSmol) |
|
| |
InChI
|
Testosterone hexahydrobenzoate (THHB), or testosterone cyclohexanecarboxylate (TCHC), sold under the brand names Testormon Depot, Sterandryl Retard, Tardosterandryl, and Testosteron-Depot among others, is an androgen and anabolic steroid medication and a testosterone ester.[1][2][3][4][5] It is used by intramuscular injection and is provided in the form of ampoules containing 100 mg THHB in oil solution.[4] THHB has comparable pharmacokinetics to those of testosterone cypionate and testosterone enanthate.[6] The medication is no longer marketed.[7] It was previously available in Great Britain.[8]
See also
References
- ^ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 641–642. ISBN 978-1-4757-2085-3.
- ^ Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. ISBN 978-3-88763-075-1.
- ^ Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. ISBN 978-94-011-4439-1.
- ^ a b Lauritzen C (1988). "Natürliche und Synthetische Sexualhormone – Biologische Grundlagen und Behandlungsprinzipien" [Natural and Synthetic Sexual Hormones – Biological Basis and Medical Treatment Principles]. In Schneider HP, Lauritzen C, Nieschlag E (eds.). Grundlagen und Klinik der Menschlichen Fortpflanzung [Foundations and Clinic of Human Reproduction] (in German). Walter de Gruyter. pp. 229–306. ISBN 978-3110109689. OCLC 35483492.
- ^ Applezweig N (1962). Steroid Drugs. Blakiston Division, McGraw-Hill. p. 441.
- ^ Behre HM, Nieschlag E, Behre H, Nieschlag S (26 July 2012). "Testosterone preparations for clinical use in males". In Nieschlag E, Behre HM, Nieschlag S (eds.). Testosterone: Action, Deficiency, Substitution. Cambridge University Press. pp. 309–335. doi:10.1017/CBO9781139003353.016. ISBN 978-1-107-01290-5.
- ^ Llewellyn W (2011). Anabolics. Molecular Nutrition Llc. ISBN 978-0-9828280-1-4.
- ^ Bishop PM (1958). "Endocrine Treatment of Gynaecological Disorders". In Gardiner-Hill H (ed.). Modern Trends in Endocrinology. Vol. 1. London: Butterworth & Co. pp. 231–244.
- v
- t
- e
(incl. AASTooltip anabolic–androgenic steroid)
ARTooltip Androgen receptor antagonists | |||||
---|---|---|---|---|---|
Steroidogenesis inhibitors |
| ||||
Antigonadotropins |
| ||||
Others |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
- See also
- Androgen receptor modulators
- Estrogens and antiestrogens
- Progestogens and antiprogestogens
- List of androgens/anabolic steroids
This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
This article about a steroid is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e